Compared with ticlopidine and clopidogrel,prasugrel is a novel platelet P2Y12 receptor antagonist,whose inhibitory effects on platelet aggregation are more effective and rapid,and the present study of which has been in Ⅲ stage clinical trial.
新一代血小板P2Y12受体阻断剂普拉格雷,与噻氯匹啶、氯吡格雷相比,能更快速、更有效地抑制血小板聚集,是一种已处于Ⅲ期临床研究中的噻吩吡啶类药物。
Prasugrel is a new generation of oral anti-platelet aggregation drug with high oral bioavailability,faster onset,and can be removed from the loading dose administration, developed by Lilly and Sankyo,used to treat atherosclerosis and acute coronary syndrome (ACS).
普拉格雷,英文名称为Prasugrel,化学名称为2-乙酰氧基-5-(α-环丙羰基-2-氟苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶,由Sankyo和Lilly共同开发的新一代口服抗血小板聚集药物,用于治疗动脉粥样硬化疾病和急性冠状动脉综合症。
